Department of Diabetes, Sud Francilien Hospital Center, Corbeil-Essonnes, France.
INSERM UMRS 1138, Cordeliers Research Center, Paris, France.
PLoS One. 2020 May 21;15(5):e0233168. doi: 10.1371/journal.pone.0233168. eCollection 2020.
Aggressive antidiabetic therapy and rapid glycemic control are associated with diabetic neuropathy. Here we investigated if this is also the case for Charcot neuroarthropathy.
HbA1c levels and other relevant data were extracted from medical databases of 44 cases of acute Charcot neuroarthropathy.
HbA1c levels significantly declined from 8.25% (67mmol/mol) 7.1%-9.4%, at -6 months (M-6), to 7.40%(54mmol/mol) [6.70%-8.03%] (50-64 mmol/mol) during the six months preceding the diagnosis of Charcot neuroarthropathy (P <0.001).
HbA1c levels significantly declined during the six months preceding the onset of Charcot neuroarthropathy. This decline seems to be a associated factor with the appearance of an active phase of Charcot neuroarthropathy in poorly controlled patients with diabetic sensitive neuropathy.
积极的降糖治疗和快速血糖控制与糖尿病周围神经病变有关。在这里,我们研究了这种情况是否也适用于夏科氏神经关节病。
从 44 例急性夏科氏神经关节病的医学数据库中提取了 HbA1c 水平和其他相关数据。
HbA1c 水平从-6 个月(M-6)时的 8.25%(67mmol/mol)[7.1%-9.4%](54-79mmol/mol)显著下降至夏科氏神经关节病诊断前 6 个月的 7.40%(54mmol/mol)[6.70%-8.03%](50-64mmol/mol)(P<0.001)。
HbA1c 水平在夏科氏神经关节病发病前 6 个月显著下降。这种下降似乎是糖尿病敏感神经病变控制不佳的患者夏科氏神经关节病活跃期出现的一个相关因素。